Based on studies within the last few years, relatively reliable data have been reported for Tremelimumab (42) (anti-CTLA4 immunoglobulin G2 (IgG2) antibody), Nivolumab (43–46) (anti-PD1 antibody), and Nivolumab in combination with Ipilimumab (47) in the treatment of patients with d MMR-MSI-H CRC (Exhibits high tumor mutational load and high number of tumor-infiltrating lymphocytes). This evidence concerns the gene CTLA4 and neoplasm.